


Amendments to the Claims

This listing of Claims will replace all prior versions and listings of the claims in the application:

Listing of Claims

1. (Original) A method of treating a disease mediated by the Cannabinoid-1 receptor comprising administration to a patient in need of such treatment of a therapeutically effective amount of a compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from:

- (1) hydrogen,
- (2) C₁₋₄alkyl,
- (3) C₂₋₄alkenyl,
- (4) C₂₋₄alkynyl,
- (5) C₃₋₇cycloalkyl,
- (6) C₃₋₇cycloalkyl-C₁₋₄alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C₁₋₄alkyl,
- (9) aryl, and
- (10) heteroaryl;

wherein alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one to four substituents independently selected from R^a, and aryl and heteroaryl are optionally substituted with one to four substituents independently selected from R^b;

R² is selected from:

- (1) -OR^c,
- (2) -OC(O)R^c,
- (3) -OC(O)NR^cR^d,
- (4) -SR^c,
- (5) -S(O)_mR^c,

- (6) $-\text{SO}_2\text{NR}^c\text{R}^d$,
- (7) $-\text{NR}^c\text{R}^d$,
- (8) $-\text{NR}^c\text{C}(\text{O})\text{R}^d$,
- (9) $-\text{NR}^c\text{SO}_2\text{R}^d$,
- (10) $-\text{NR}^c\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (11) $-\text{NR}^c\text{C}(\text{O})\text{OR}^d$,
- (12) $-\text{C}(\text{O})\text{OR}^c$, and
- (13) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$;

R^3 is selected from:

- (1) $-\text{C}_{1-10}\text{alkyl}$, and
- (2) $-\text{Ar}^2$;

Ar^1 and Ar^2 are independently selected from phenyl, naphthyl, thienyl, furanyl, pyrrolyl, benzothienyl, benzofuranyl, indanyl, indenyl, indolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl, each optionally substituted with one, two, or three groups independently selected from R^b ;

each R^a is independently selected from:

- (1) $-\text{OR}^c$,
- (2) $-\text{NR}^c\text{S}(\text{O})_m\text{R}^d$,
- (3) halogen,
- (4) $-\text{S}(\text{O})_m\text{R}^c$,
- (5) $-\text{SR}^c$,
- (6) $-\text{S}(\text{O})_2\text{OR}^c$,
- (7) $-\text{S}(\text{O})_m\text{NR}^c\text{R}^d$,
- (8) $-\text{NR}^c\text{R}^d$,
- (9) $-\text{O}(\text{CR}^e\text{R}^f)_n\text{NR}^c\text{R}^d$,
- (10) $-\text{C}(\text{O})\text{R}^c$,
- (11) $-\text{CO}_2\text{R}^c$,
- (12) $-\text{CO}_2(\text{CR}^e\text{R}^f)_n\text{CONR}^c\text{R}^d$,
- (13) $-\text{OC}(\text{O})\text{R}^c$,
- (14) $-\text{CN}$,
- (15) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (16) $-\text{NR}^c\text{C}(\text{O})\text{R}^d$,
- (17) $-\text{OC}(\text{O})\text{NR}^c\text{R}^d$,
- (18) $-\text{NR}^c\text{C}(\text{O})\text{OR}^d$,
- (19) $-\text{NR}^c\text{C}(\text{O})\text{NR}^c\text{R}^d$,

- (20) $-\text{CR}^c(\text{N}-\text{OR}^d)$,
- (21) $-\text{CF}_3$,
- (22) $-\text{OCF}_3$,
- (23) C_3 -8cycloalkyl, and
- (24) cycloheteroalkyl;

each R^b is independently selected from:

- (1) C_{1-6} alkyl,
- (2) C_{2-6} alkenyl,
- (3) C_{2-6} alkynyl,
- (4) $-\text{OR}^c$,
- (5) $-\text{NR}^c\text{S}(\text{O})_m\text{R}^d$,
- (6) $-\text{NO}_2$,
- (7) halogen,
- (8) $-\text{S}(\text{O})_m\text{R}^c$,
- (9) $-\text{SR}^c$,
- (10) $-\text{S}(\text{O})_2\text{OR}^c$,
- (11) $-\text{S}(\text{O})_m\text{NR}^c\text{R}^d$,
- (12) $-\text{NR}^c\text{R}^d$,
- (13) $-\text{O}(\text{CR}^e\text{R}^f)_n\text{NR}^c\text{R}^d$,
- (14) $-\text{C}(\text{O})\text{R}^c$,
- (15) $-\text{CO}_2\text{R}^c$,
- (16) $-\text{CO}_2(\text{CR}^e\text{R}^f)_n\text{CONR}^c\text{R}^d$,
- (17) $-\text{OC}(\text{O})\text{R}^c$,
- (18) $-\text{CN}$,
- (19) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (20) $-\text{NR}^c\text{C}(\text{O})\text{R}^d$,
- (21) $-\text{OC}(\text{O})\text{NR}^c\text{R}^d$,
- (22) $-\text{NR}^c\text{C}(\text{O})\text{OR}^d$,
- (23) $-\text{NR}^c\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (24) $-\text{CR}^c(\text{N}-\text{OR}^d)$,
- (25) $-\text{CF}_3$,
- (26) $-\text{OCF}_3$,
- (27) C_3 -8cycloalkyl,
- (28) cycloheteroalkyl, and
- (29) phenyl;

each R^c and R^d is independently selected from:

- (1) hydrogen,
- (2) C_{1-10} alkyl,
- (3) C_{2-10} alkenyl,
- (4) C_{2-10} alkynyl,
- (5) $-NH(C_{1-10}alkyl)$,
- (6) $-N(C_{1-10}alkyl)_2$,
- (7) cycloalkyl,
- (8) cycloalkyl- $C_{1-10}alkyl$;
- (9) cycloheteroalkyl,
- (10) cycloheteroalkyl- $C_{1-10}alkyl$;
- (11) aryl,
- (12) heteroaryl,
- (13) aryl- $C_{1-10}alkyl$, and
- (14) heteroaryl- $C_{1-10}alkyl$, or

R^c and R^d together with the atom to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N- R^c ,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^e ;

each R^e and R^f is independently selected from:

- (1) hydrogen,
- (2) $C_{1-10}alkyl$,
- (3) C_{2-10} alkenyl,
- (4) $C_{2-10}alkynyl$,
- (5) cycloalkyl,
- (6) cycloalkyl- $C_{1-10}alkyl$,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl- $C_{1-10}alkyl$,
- (9) aryl,
- (10) heteroaryl,
- (11) aryl- $C_{1-10}alkyl$, and
- (12) heteroaryl- $C_{1-10}alkyl$, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

m is selected from 1 and 2; and

n is selected from 1, 2, and 3.

2. (Original) The method according to Claim 1 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

3. (Original) The method according to Claim 2 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

4. (Original) The method according to Claim 3 wherein the eating disorder associated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

5. (Original) The method according to Claim 4 wherein the eating disorder associated with excessive food intake is obesity.

6. (Original) The method according to Claim 1, wherein in the compound of structural formula I:

R¹ is selected from:

- (1) hydrogen,
- (2) C₁₋₄alkyl,
- (3) C₂₋₄alkenyl,
- (4) C₂₋₄alkynyl,
- (5) C₃₋₇cycloalkyl, and
- (6) C₃₋₇cycloalkyl-C₁₋₄alkyl,

wherein alkyl, alkenyl, alkynyl, and cycloalkyl, are optionally substituted with one to four substituents independently selected from R^a;

R² is selected from:

- (1) -OR^c,
- (2) -SR^c,
- (3) -S(O)_mR^c,
- (4) -SO₂NR^cR^d,
- (5) -NR^cR^d,
- (6) -NR^cC(O)R^d,

- (7) $-\text{NR}^{\text{c}}\text{SO}_2\text{R}^{\text{d}}$,
- (8) $-\text{C}(\text{O})\text{OR}^{\text{c}}$, and
- (9) $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$;

R^3 is selected from:

- (1) $-\text{C}_{1-4}$ alkyl, and
- (2) $-\text{Ar}^2$;

Ar^1 and Ar^2 are independently selected from phenyl, naphthyl, thienyl, each optionally substituted with one or two groups independently selected from R^{b} ;

each R^{a} is independently selected from:

- (1) $-\text{OR}^{\text{c}}$,
- (2) $-\text{NR}^{\text{c}}\text{S}(\text{O})_m\text{R}^{\text{d}}$,
- (3) halogen,
- (4) $-\text{S}(\text{O})_m\text{R}^{\text{c}}$,
- (5) $-\text{SR}^{\text{c}}$,
- (6) $-\text{S}(\text{O})_m\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
- (7) $-\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
- (8) $-\text{O}(\text{CR}^{\text{e}}\text{R}^{\text{f}})_n\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
- (9) $-\text{C}(\text{O})\text{R}^{\text{c}}$,
- (10) $-\text{CN}$,
- (11) $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
- (12) $-\text{NR}^{\text{c}}\text{C}(\text{O})\text{R}^{\text{d}}$,
- (13) $-\text{CF}_3$,
- (14) $-\text{OCF}_3$,
- (15) C_3 -8cycloalkyl, and
- (16) cycloheteroalkyl;

each R^{b} is independently selected from:

- (1) C_{1-6} alkyl,
- (2) $-\text{OR}^{\text{c}}$,
- (3) halogen,
- (4) $-\text{CN}$,
- (5) $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
- (6) $-\text{NR}^{\text{c}}\text{C}(\text{O})\text{R}^{\text{d}}$,
- (7) CF_3 ,
- (8) $-\text{OCF}_3$, and
- (9) phenyl;

each R^c and R^d is independently selected from:

- (1) hydrogen,
- (2) $-C_{1-10}$ alkyl,
- (3) $-NH(C_{1-10}$ alkyl),
- (4) $-N(C_{1-10}$ alkyl)₂,
- (5) cycloalkyl, and
- (6) cycloheteroalkyl, or

R^c and R^d together with the atom to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N- R^c ,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^e ;

each R^e and R^f is independently selected from:

- (1) hydrogen,
- (2) C_{1-10} alkyl,
- (3) cycloheteroalkyl,
- (4) cycloheteroalkyl- C_{1-10} alkyl,
- (5) aryl,
- (6) heteroaryl,
- (7) aryl- C_{1-10} alkyl, and
- (8) heteroaryl- C_{1-10} alkyl, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

or a pharmaceutically acceptable salt thereof.

7. (Original) The method according to Claim 6, wherein in the compound of structural formula I:

R^1 is selected from:

- (1) hydrogen, and
- (2) C_{1-4} alkyl;

R^2 is selected from:

- (1) $-OR^c$,
- (2) $-NR^cR^d$,
- (3) $-NR^cC(O)R^d$,
- (4) $-NR^cSO_2R^d$,
- (5) $-C(O)OR^c$, and
- (6) $-C(O)NR^cR^d$;

R^3 is selected from:

(1) – methyl, and

(2) – Ar²;

Ar¹ and Ar² are phenyl, each optionally substituted with one or two groups independently selected from R^b;

each R^e and R^f is independently selected from:

(1) hydrogen,

(2) C₁₋₁₀alkyl,

(3) cycloheteroalkyl,

(4) aryl, and

(5) heteroaryl;

or a pharmaceutically acceptable salt thereof.

8. (Original) The method according to Claim 7, wherein in the compound of structural formula I:

R¹ is selected from:

(1) hydrogen,

(2) methyl, and

(3) ethyl;

R² is selected from:

(1) –OR^c,

(2) –NR^cC(O)R^d,

(3) –C(O)OR^c, and

(4) –C(O)NR^cR^d;

Ar¹ and Ar² are each independently selected from:

(1) phenyl,

(2) 4-fluorophenyl,

(3) 2-chlorophenyl,

(4) 3-chlorophenyl,

(5) 4-chlorophenyl,

(6) 4-cyanophenyl,

(7) 4-methylphenyl,

(8) 4-isopropylphenyl,

(9) 4-biphenyl,

(10) 4-bromophenyl,

(11) 4-iodophenyl,

(12) 2,4-dichlorophenyl, and

(13) 2-chloro-4-fluorophenyl;

each R^c and R^d is independently selected from:

- (1) hydrogen,
- (2) methyl,
- (3) ethyl,
- (4) -N(CH₃)₂,
- (5) -NH(CH₃),
- (6) cyclopentane,
- (7) cyclohexane,
- (8) cycloheptane,
- (9) piperidine,
- (10) morpholine,
- (11) pyrrolidine,
- (12) azepine, and
- (13) 4-methylpiperazine,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^e; or a pharmaceutically acceptable salt thereof.

9. (Original) The method according to Claim 8, wherein in the compound according to structural formula I:

R¹ is methyl;

R² is -C(O)NR^cR^d;

R³ is -Ar²;

Ar¹ is 2,4-dichlorophenyl;

Ar² is 4-chlorophenyl;

each R^c and R^d is independently selected from:

- (1) hydrogen,
- (2) cyclohexane, and
- (3) piperidine,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^e; or a pharmaceutically acceptable salt thereof.

10. (Original) The method according to Claim 1, wherein the compound of structural formula I is selected from:

- (1) ethyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxylate;
- (2) ethyl 2-(2,4-dichlorophenyl)-1,5-dimethyl-imidazole-4-carboxylate;

- (3) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (4) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (5) N-(piperidin-1-yl)-2-(2,4-dichlorophenyl)-1,5-dimethyl-imidazole-4-carboxamide;
- (6) N-(cyclopentyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (7) N-(cycloheptyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (8) N-(morpholin-4-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (9) N-(pyrrolidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (10) N-(azepin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (11) N-(4-methylpiperazin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (12) N',N'-dimethyl-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxhydrazide;
- (13) N-(cyclohexyl)-1-(phenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (14) N-(piperidin-1-yl)-1-(phenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (15) N-(cyclohexyl)-1-(4-fluorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (16) N-(piperidin-1-yl)-1-(4-fluorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (17) N-(4-methyl-cyclohexyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide (Isomer A);
- (18) N-(2-(pyrrolidin-1-yl)ethyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (19) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2-chlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (20) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2-chlorophenyl)-5-methyl-imidazole-4-carboxamide;

- (21) N-(cyclohexyl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (22) N-(piperidin-1-yl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (23) N-(cyclohexyl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (24) N-(piperidin-1-yl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (25) N-(cyclohexyl)-1-(4-cyanophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (26) N-(piperidin-1-yl)-1-(4-cyanophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (27) N-(cyclohexyl)-1-(4-biphenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (28) N-(piperidin-1-yl)-1-(4-biphenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (29) N-(cyclohexyl)-1,2-bis(4-chlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (30) N-(piperidin-1-yl)-1,2-bis(4-chlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (31) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (32) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (33) N-(cyclohexyl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (34) N-(piperidin-1-yl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (35) N-(cyclohexyl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (36) N-(piperidin-1-yl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (37) N-(cyclohexyl)-1-(3-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (38) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2-chloro-4-fluorophenyl)-5-methyl-imidazole-4-carboxamide;

- (39) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2-chloro-4-fluorophenyl)-5-methyl-imidazole-4-carboxamide;
- (40) N-(cyclohexyl)-1-(2-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide; and
- (41) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(3-chlorophenyl)-5-methyl-imidazole-4-carboxamide;


or a pharmaceutically acceptable salt thereof.

11. (Original) The method according to Claim 10, wherein the compound of structural formula I is selected from:

- (1) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (2) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (3) N-(cyclohexyl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (4) N-(cyclohexyl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (5) N-(cyclohexyl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide; and
- (6) N-(cycloheptyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;

or a pharmaceutically acceptable salt thereof.

12. (Original) A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 mg to about 100 mg per kg of a compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from:

- (1) hydrogen,
- (2) C₁₋₄alkyl,
- (3) C₂₋₄alkenyl,
- (4) C₂₋₄alkynyl,
- (5) C₃₋₇cycloalkyl,
- (6) C₃₋₇cycloalkyl-C₁₋₄alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C₁₋₄alkyl,
- (9) aryl, and
- (10) heteroaryl;

wherein alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one to four substituents independently selected from R^a, and aryl and heteroaryl are optionally substituted with one to four substituents independently selected from R^b;

R² is selected from:

- (1) -OR^c,
- (2) -OC(O)R^c,
- (3) -OC(O)NR^cR^d,
- (4) -SR^c,
- (5) -S(O)_mR^c,
- (6) -SO₂NR^cR^d,
- (7) -NR^cR^d,
- (8) -NR^cC(O)R^d,
- (9) -NR^cSO₂R^d,
- (10) -NR^cC(O)NR^cR^d,
- (11) -NR^cC(O)OR^d,
- (12) -C(O)OR^c, and
- (13) -C(O)NR^cR^d;

R³ is selected from:

- (1) -C₁₋₁₀alkyl, and
- (2) -Ar²;

Ar¹ and Ar² are independently selected from phenyl, naphthyl, thienyl, furanyl, pyrrolyl, benzothienyl, benzofuranyl, indanyl, indenyl, indolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl, each optionally substituted with one, two, or three groups independently selected from R^b;

each R^a is independently selected from:

- (1) $-OR^c$,
- (2) $-NR^cS(O)_mR^d$,
- (3) halogen,
- (4) $-S(O)_mR^c$,
- (5) $-SR^c$,
- (6) $-S(O)_2OR^c$,
- (7) $-S(O)_mNR^cR^d$,
- (8) $-NR^cR^d$,
- (9) $-O(CR^eR^f)_nNR^cR^d$,
- (10) $-C(O)R^c$,
- (11) $-CO_2R^c$,
- (12) $-CO_2(CR^eR^f)_nCONR^cR^d$,
- (13) $-OC(O)R^c$,
- (14) $-CN$,
- (15) $-C(O)NR^cR^d$,
- (16) $-NR^cC(O)R^d$,
- (17) $-OC(O)NR^cR^d$,
- (18) $-NR^cC(O)OR^d$,
- (19) $-NR^cC(O)NR^cR^d$,
- (20) $-CR^c(N-OR^d)$,
- (21) $-CF_3$,
- (22) $-OCF_3$,
- (23) C_3 -gycloalkyl, and
- (24) cycloheteroalkyl;

each R^b is independently selected from:

- (1) C_1 -6alkyl,
- (2) C_2 -6alkenyl,
- (3) C_2 -6alkynyl,
- (4) $-OR^c$,
- (5) $-NR^cS(O)_mR^d$,
- (6) $-NO_2$,
- (7) halogen,
- (8) $-S(O)_mR^c$,
- (9) $-SR^c$,

- (10) $-S(O)_2OR^c$,
- (11) $-S(O)_mNR^cR^d$,
- (12) $-NR^cR^d$,
- (13) $-O(CR^eR^f)_nNR^cR^d$,
- (14) $-C(O)R^c$,
- (15) $-CO_2R^c$,
- (16) $-CO_2(CR^eR^f)_nCONR^cR^d$,
- (17) $-OC(O)R^c$,
- (18) $-CN$,
- (19) $-C(O)NR^cR^d$,
- (20) $-NR^cC(O)R^d$,
- (21) $-OC(O)NR^cR^d$,
- (22) $-NR^cC(O)OR^d$,
- (23) $-NR^cC(O)NR^cR^d$,
- (24) $-CR^c(N-OR^d)$,
- (25) $-CF_3$,
- (26) $-OCF_3$,
- (27) C_{3-8} cycloalkyl,
- (28) cycloheteroalkyl, and
- (29) phenyl;

each R^c and R^d is independently selected from:


- (1) hydrogen,
- (2) C_{1-10} alkyl,
- (3) C_{2-10} alkenyl,
- (4) C_{2-10} alkynyl,
- (5) $-N(C_{1-10}alkyl)_2$,
- (6) $-NH(C_{1-10}alkyl)$,
- (7) cycloalkyl,
- (8) cycloalkyl- $C_{1-10}alkyl$;
- (9) cycloheteroalkyl,
- (10) cycloheteroalkyl- $C_{1-10}alkyl$;
- (11) aryl,
- (12) heteroaryl,
- (13) aryl- $C_{1-10}alkyl$, and
- (14) heteroaryl- $C_{1-10}alkyl$, or

R^c and R^d together with the atom to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-RC, each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^e; each R^e and R^f is independently selected from:

- (1) hydrogen,
- (2) C₁₋₁₀alkyl,
- (3) C₂₋₁₀ alkenyl,
- (4) C₂₋₁₀alkynyl,
- (5) cycloalkyl,
- (6) cycloalkyl-C₁₋₁₀ alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C₁₋₁₀ alkyl,
- (9) aryl,
- (10) heteroaryl,
- (11) aryl-C₁₋₁₀ alkyl, and
- (12) heteroaryl-C₁₋₁₀ alkyl, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen; m is selected from 1 and 2; and n is selected from 1, 2, and 3.

13. (Original) A compound of structural formula I:



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from: methyl and ethyl,

wherein methyl and ethyl are optionally substituted with one to four substituents independently selected from R^a;

R² is selected from:

- (1) -C(O)OR^c, and
- (2) -C(O)NR^cR^d;

R³ is selected from methyl and Ar²;

Ar¹ and Ar² are phenyl, each optionally substituted with one, two, or three groups independently selected from R^b;

each R^a is independently selected from:

- (1) -OR^c,
- (2) -NR^cS(O)_mR^d,
- (3) halogen,
- (4) -S(O)_mR^c,
- (5) -SR^c,
- (6) -S(O)_mNR^cR^d,
- (7) -NR^cR^d,
- (8) -O(CR^eR^f)_nNR^cR^d,
- (9) -C(O)R^c,
- (10) -CN,
- (11) -C(O)NR^cR^d,
- (12) -NR^cC(O)R^d,
- (13) -CF₃, and
- (14) -OCF₃;

each R^b is independently selected from: halogen, C₁₋₃alkyl, -CN, and phenyl;

each R^c and R^d is independently selected from:

- (1) hydrogen,
- (2) C₁₋₁₀alkyl,
- (3) C₂₋₁₀alkenyl,
- (4) C₂₋₁₀alkynyl,
- (5) -NH(C₁₋₁₀alkyl),
- (6) -N(C₁₋₁₀alkyl)₂,
- (7) cycloalkyl,
- (8) cycloalkyl-C₁₋₁₀alkyl,
- (9) cycloheteroalkyl,
- (10) cycloheteroalkyl-C₁₋₁₀alkyl,

- (11) aryl,
- (12) heteroaryl,
- (13) aryl-C₁₋₁₀alkyl, and
- (14) heteroaryl-C₁₋₁₀alkyl, or

R^c and R^d together with the atom to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R^c, each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^e; each R^e and R^f is independently selected from:

- (1) hydrogen,
- (2) C₁₋₁₀alkyl,
- (3) C₂₋₁₀alkenyl,
- (4) C₂₋₁₀alkynyl,
- (5) cycloalkyl,
- (6) cycloalkyl-C₁₋₁₀alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C₁₋₁₀alkyl,
- (9) aryl,
- (10) heteroaryl,
- (11) aryl-C₁₋₁₀alkyl, and
- (12) heteroaryl-C₁₋₁₀alkyl, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen; m is selected from 1 and 2; and n is selected from 1, 2, and 3.

14. (Original) The compound of claim 13 wherein:

R¹ is methyl;

R² is -C(O)NR^cR^d;

R³ is selected from methyl and Ar²;

Ar¹ is phenyl substituted at the 2 and 4 positions with a substituent independently selected from R^b;

Ar² is independently selected from:

- (1) phenyl,
- (2) 4-fluorophenyl,
- (3) 2-chlorophenyl,
- (4) 3-chlorophenyl,

- (5) 4-chlorophenyl,
- (6) 4-cyanophenyl,
- (7) 4-methylphenyl,
- (8) 4-isopropylphenyl,
- (9) 4-biphenyl,
- (10) 4-bromophenyl,
- (11) 4-iodophenyl,
- (12) 2,4-dichlorophenyl, and
- (13) 2-chloro-4-fluorophenyl;

each R^c and R^d is independently selected from:

- (1) hydrogen,
- (2) methyl,
- (3) ethyl,
- (4) -N(CH₃)₂,
- (5) -NH(CH₃),
- (6) cyclopentane,
- (7) cyclohexane,
- (8) cycloheptane,
- (9) piperidine
- (10) morpholine,
- (11) pyrrolidine,
- (12) azepine, and
- (13) 4-methylpiperazine,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^e; or a pharmaceutically acceptable salt thereof.

15. (Original) A compound selected from:

- (1) ethyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxylate;
- (2) ethyl 2-(2,4-dichlorophenyl)-1,5-dimethyl-imidazole-4-carboxylate;
- (3) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (4) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (5) N-(piperidin-1-yl)-2-(2,4-dichlorophenyl)-1,5-dimethyl-imidazole-4-carboxamide;

- (6) N-(cyclopentyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (7) N-(cycloheptyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (8) N-(morpholin-4-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (9) N-(pyrrolidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (10) N-(azepin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (11) N-(4-methylpiperazin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (12) N',N'-dimethyl-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxhydrazide;
- (13) N-(cyclohexyl)-1-(phenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (14) N-(piperidin-1-yl)-1-(phenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (15) N-(cyclohexyl)-1-(4-fluorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (16) N-(piperidin-1-yl)-1-(4-fluorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (17) N-(4-methyl-cyclohexyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide (Isomer A);
- (18) N-(2-(pyrrolidin-1-yl)ethyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (19) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2-chlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (20) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2-chlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (21) N-(cyclohexyl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (22) N-(piperidin-1-yl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (23) N-(cyclohexyl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;

- (24) N-(piperidin-1-yl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (25) N-(cyclohexyl)-1-(4-cyanophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (26) N-(piperidin-1-yl)-1-(4-cyanophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (27) N-(cyclohexyl)-1-(4-biphenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (28) N-(piperidin-1-yl)-1-(4-biphenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (29) N-(cyclohexyl)-1,2-bis(4-chlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (30) N-(piperidin-1-yl)-1,2-bis(4-chlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (31) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (32) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (33) N-(cyclohexyl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (34) N-(piperidin-1-yl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (35) N-(cyclohexyl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (36) N-(piperidin-1-yl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (37) N-(cyclohexyl)-1-(3-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (38) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2-chloro-4-fluorophenyl)-5-methyl-imidazole-4-carboxamide;
- (39) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2-chloro-4-fluorophenyl)-5-methyl-imidazole-4-carboxamide;
- (40) N-(cyclohexyl)-1-(2-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide; and
- (41) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(3-chlorophenyl)-5-methyl-imidazole-4-carboxamide;

or a pharmaceutically acceptable salt thereof.

16. (Original) The compound according to Claim 15 selected from:

- (1) N-(cyclohexyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (2) N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;
- (3) N-(cyclohexyl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (4) N-(cyclohexyl)-1-(4-isopropylphenyl)-2-(2,4-dichlorophenyl)-5-ethyl-imidazole-4-carboxamide;
- (5) N-(cyclohexyl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide; and
- (6) N-(cycloheptyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-imidazole-4-carboxamide;

or a pharmaceutically acceptable salt thereof.


17. (Original) A composition comprising a compound according to Claim 13 and a pharmaceutically acceptable carrier.

18. (Original) A composition comprising a compound according to Claim 15 and a pharmaceutically acceptable carrier.

19. (Original) A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 to about 100 mg/kg of a compound according to Claim 13.

20. (Original) A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 to about 100 mg/kg of a compound according to Claim 15.

21. (Amended) A composition comprising a pharmaceutically effective amount of a compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from:

- (1) hydrogen,
- (2) C₁₋₄alkyl,
- (3) C₂₋₄alkenyl,
- (4) C₂₋₄alkynyl,
- (5) C₃₋₇cycloalkyl,
- (6) C₃₋₇cycloalkyl-C₁₋₄alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C₁₋₄alkyl,
- (9) aryl, and
- (10) heteroaryl;

wherein alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one to four substituents independently selected from R^a, and aryl and heteroaryl are optionally substituted with one to four substituents independently selected from R^b;

R² is selected from:

- (1) -OR^c,
- (2) -OC(O)R^c,
- (3) -OC(O)NR^cR^d,
- (4) -SR^c,
- (5) -S(O)_mR^c,
- (6) -SO₂NR^cR^d,
- (7) -NR^cR^d,
- (8) -NR^cC(O)R^d,
- (9) -NR^cSO₂R^d,
- (10) -NR^cC(O)NR^cR^d,
- (11) -NR^cC(O)OR^d,
- (12) -C(O)OR^c, and
- (13) -C(O)NR^cR^d;

R³ is selected from:

- (1) -C₁₋₁₀alkyl, and
- (2) -Ar²;

Ar¹ and Ar² are independently selected from phenyl, naphthyl, thienyl, furanyl, pyrrolyl, benzothienyl, benzofuranyl, indanyl, indenyl, indolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl, each optionally substituted with one, two, or three groups independently selected from R^b;

each R^a is independently selected from:

- (1) -OR^c,
- (2) -NR^cS(O)_mR^d,
- (3) halogen,
- (4) -S(O)_mR^c,
- (5) -SR^c,
- (6) -S(O)₂OR^c,
- (7) -S(O)_mNR^cR^d,
- (8) -NR^cR^d,
- (9) -O(CR^eR^f)_nNR^cR^d,
- (10) -C(O)R^c,
- (11) -CO₂R^c,
- (12) -CO₂(CR^eR^f)_nCONR^cR^d,
- (13) -OC(O)R^c,
- (14) -CN,
- (15) -C(O)NR^cR^d,
- (16) -NR^cC(O)R^d,
- (17) -OC(O)NR^cR^d,
- (18) -NR^cC(O)OR^d,
- (19) -NR^cC(O)NR^cR^d,
- (20) -CR^c(N-OR^d),
- (21) -CF₃,
- (22) -OCF₃,
- (23) C₃₋₈cycloalkyl, and
- (24) cycloheteroalkyl;

each R^b is independently selected from:

- (1) C₁₋₆alkyl,
- (2) C₂₋₆alkenyl,
- (3) C₂₋₆alkynyl,
- (4) -OR^c,
- (5) -NR^cS(O)_mR^d,

- (6) $-\text{NO}_2$,
- (7) halogen,
- (8) $-\text{S}(\text{O})_m\text{R}^c$,
- (9) $-\text{SR}^c$,
- (10) $-\text{S}(\text{O})_2\text{OR}^c$,
- (11) $-\text{S}(\text{O})_m\text{NR}^c\text{R}^d$,
- (12) $-\text{NR}^c\text{R}^d$,
- (13) $-\text{O}(\text{CR}^e\text{R}^f)_n\text{NR}^c\text{R}^d$,
- (14) $-\text{C}(\text{O})\text{R}^c$,
- (15) $-\text{CO}_2\text{R}^c$,
- (16) $-\text{CO}_2(\text{CR}^e\text{R}^f)_n\text{CONR}^c\text{R}^d$,
- (17) $-\text{OC}(\text{O})\text{R}^c$,
- (18) $-\text{CN}$,
- (19) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (20) $-\text{NR}^c\text{C}(\text{O})\text{R}^d$,
- (21) $-\text{OC}(\text{O})\text{NR}^c\text{R}^d$,
- (22) $-\text{NR}^c\text{C}(\text{O})\text{OR}^d$,
- (23) $-\text{NR}^c\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (24) $-\text{CR}^c(\text{N}-\text{OR}^d)$,
- (25) $-\text{CF}_3$,
- (26) $-\text{OCF}_3$,
- (27) C_3 -8cycloalkyl,
- (28) cycloheteroalkyl, and
- (29) phenyl;

each R^c and R^d is independently selected from:

- (1) hydrogen,
- (2) C_1 -10alkyl,
- (3) C_2 -10alkenyl,
- (4) C_2 -10alkynyl,
- (5) $-\text{NH}(\text{C}_1$ -10alkyl),
- (6) $-\text{N}(\text{C}_1$ -10alkyl) $_2$,
- (7) cycloalkyl,
- (8) cycloalkyl- C_1 -10alkyl;
- (9) cycloheteroalkyl,
- (10) cycloheteroalkyl- C_1 -10alkyl;

- (11) aryl,
- (12) heteroaryl,
- (13) aryl-C₁₋₁₀alkyl, and
- (14) heteroaryl-C₁₋₁₀alkyl, or

R^c and R^d together with the atom to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R^c;

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^e;

each R^e and R^f is independently selected from:

- (1) hydrogen,
- (2) C₁₋₁₀alkyl,
- (3) C₂₋₁₀alkenyl,
- (4) C₂₋₁₀alkynyl,
- (5) cycloalkyl,
- (6) cycloalkyl-C₁₋₁₀alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C₁₋₁₀alkyl,
- (9) aryl,
- (10) heteroaryl,
- (11) aryl-C₁₋₁₀alkyl, and
- (12) heteroaryl-C₁₋₁₀alkyl, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

m is selected from 1 and 2; and

n is selected from 1, 2, and 3;

and an anorectic agent selected from: aminorex, amphetamine, benzphetamine, chlorphentermine, clobenzorex, cloforex, clominorex, clortermine, cyclexedrine, dexfenfluramine, dextroamphetamine, diethylpropion, diphemethoxidine, *N*-ethylamphetamine, fenbutrazate, fenfluramine, fenisorex, fenproporex, fludorex, fluminorex, furfurylmethylamphetamine, levamfetamine, levophacetoperane, mazindol, mefenorex, metamfepramone, methamphetamine, norpseudoephedrine, pentorex, phendimetrazine, phenmetrazine, phentermine, phenylpropanolamine, picilorex and sibutramine; or

a selective serotonin reuptake inhibitor selected from: fluoxetine, fluvoxamine, paroxetine and sertraline;

or an antidepressant agent selected from: norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, reversible inhibitors of monoamine oxidase, serotonin

and noradrenaline reuptake inhibitors, corticotropin releasing factor antagonists, α -adrenoreceptor antagonists and atypical anti-depressants; or the VLA-4 antagonist natalizumab; or a steroid or corticosteroid selected from: beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone; or an antihistamine selected from: bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripeleminamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, desloratadine, cetirizine, fexofenadine, and descarboethoxyloratadine; or a non-steroidal anti-asthmatics selected from: theophylline, cromolyn sodium, atropine, and ipratropium bromide; or a β 2-agonist selected from: terbutaline, metaproterenol, fenoterol, isoetharine, albuterol, bitolterol, salmeterol, epinephrine, and pirbuterol; or a leukotriene antagonist selected from: zafirlukast, montelukast, pranlukast, iralukast, pobelukast, and SKB-106,203; or a leukotriene biosynthesis inhibitors selected from: zileuton, and BAY-1005; or an anti-cholinergic agent selected from ipratropium bromide and atropine; or an antagonist of the CCR-3 chemokine receptors; or an osmotic agent selected from sorbitol, lactulose, polyethylene glycol, magnesium, phosphate, and sulfate; or a laxative selected from: magnesium and docusate sodium; or a bulking agent selected from: psyllium, methylcellulose, and calcium polycarbophil; or a stimulant selected from an anthroquinone, and phenolphthalein; or a corticosteroid; or penicillamine; or colchicine; or an interferon- γ , 2-oxoglutarate analog; or a prostaglandin analog; or an anti-inflammatory drug selected from: azathioprine, methotrexate, leflunamide, indomethacin, and naproxen;

and a pharmaceutically acceptable carrier.

22.-31. (Cancelled)